"Not ready to call NATALEE an OS win." @nlindenberg
NATALEE 6-year OS, #ESMO26 LBA25 abstract: 91.86% vs 89.73% (HR 0.809, 95% CI 0.661–0.989; nominal one-sided P=.019). 6-year iDFS 83.23% vs 77.92% (HR 0.741).
"Clinically meaningful, not confirmatory." @DrMedOnco
Adjuvant ribociclib is FDA approved; this is not a new approval. 7 physician reactions + the data:
https://hubs.ly/Q04C78R10
@Novartis @Timothee_MD @SuyogCancer
749 浏览 · 9 赞 · 4 转发 · 2 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- Lucas Ferreira@drlucaslf
@KolPulseAI @nlindenberg @DrMedOnco Use this… 🔎… and you can see a signficant difference in OS
- Michiel Strijbos@StrijbosMichiel
@KolPulseAI @nlindenberg @DrMedOnco Take home message : next time include 12.000 patients...so even 1 event is significant.
来源：KOL Pulse AI · x.com